[Edaily Reporter YU JIN-HEE ] Laser medical device specialist Laseroptek Co., Ltd.(199550)is accelerating its push into the Central and South American melasma treatment market. Laseroptek Co., Ltd. announced on the 13th that it participated in the “3rd SINMELASMA International Conference,” held for three days from the 6th to the 8th at the Hilton Reforma Hotel in Mexico City, where it presented clinical case studies on the use of the “HELIOS 785 PICO” for melasma treatment.

SINMELASMA is an international academic organization specializing in melasma and pigmentary disorders that was established in Latin America. Unlike general dermatology and aesthetic medicine societies, it serves as a platform for academic research and clinical advancement focused specifically on the field of melasma.

Christopher Dalton, Vice President of Laseroptek Co., Ltd.’s U.S. subsidiary, attended the conference alongside Laseroptek Co., Ltd.’s local distributor in Mexico, where they actively networked with medical professionals and industry representatives from Central and South America.

In particular, Dr. Jose Antonio Tabush, a dermatologist from Costa Rica, delivered a lecture and conducted a live demonstration on melasma treatment using Laseroptek Co., Ltd.’s Helios 785 Pico, which was very well received by attendees.

In his lecture titled “A Paradigm Shift in the Use of 785 nm Picosecond Lasers for Melasma Treatment,” Dr. Tabush shared his precise treatment approach and clinical experience using the 785 nm wavelength. The subsequent live demonstration on “Melasma Treatment Using the 785 nm Picosecond Laser” drew a crowd of approximately 500 medical professionals and industry representatives, who observed the actual procedure and its excellent treatment outcomes.

The Helios 785 Pico is Laseroptek Co., Ltd.’s flagship device, equipped with a 785nm picosecond laser developed in-house. The 785nm wavelength exhibits high selective absorption by melanin, making it exceptionally effective for treating pigmented lesions.

In addition, it offers 532nm and 1064nm wavelengths, enabling the development of multifaceted treatment strategies tailored to various pigmentary disorders and individual skin types.

Latin America is a key market with steep growth potential in the field of melasma treatment. With a large population of people with relatively dark skin—Fitzpatrick skin types III through V—and high levels of sunlight, the region sees very high clinical interest and treatment demand among medical professionals for pigmentary disorders such as melasma.

Lee Chang-jin, CEO of Laseroptek Co., Ltd., emphasized, “Latin America is a strategically vital market due to the high demand for melasma and pigmentary disorder treatments,” adding, “We will use our participation in this academic conference as an opportunity to further strengthen academic exchanges and marketing activities with local medical professionals to solidify the market position of the Helios 785 Pico.”